Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Enhancing real-world data (RWD) quality in oncology: Implementation of the qcard initiative in a large US oncology electronic health record (EHR)-derived database for research and regulatory decision-making

Zhaohui Su, Lisa Herms, Aniketh Talwai et al. Nov 03, 2025 pp. 8138-8138 10.1182/blood-2025-8138

Abstract BACKGROUND: The Oncology Quality, Characterization, and Assessment of Real-world Data (QCARD) Initiative, led b...

A laser-based nanoparticle platform to enhance T cell–Mediated immunity without direct tumor access

John Weber, Isabella Stathas, Athena Demeros et al. Nov 03, 2025 pp. 1537-1537 10.1182/blood-2025-1537

Abstract Introduction: T cell-based therapies have revolutionized cancer treatment. Chimeric antigen receptor (CAR) T cell therapy has trans...

CD84-CD3 bispecific antibody achieves potent anti-leukemic activity with favorable safety profile in Acute Myeloid Leukemia

Nanfang Zhuo, Fujie Shi, Xiangjie Lin et al. Nov 03, 2025 pp. 2355-2355 10.1182/blood-2025-2355

Abstract Title CD84-CD3 Bispecific Antibody Achieves Potent Anti-Leukemic Activity with Favorable Safety Profile in Acute Myeloid Leukemia...

Emergency department presentation is an independent driver of mortality, complications, and disparities in Acute Myeloid Leukemia: A national propensity-matched Study

Syeda Ashna Fatima Kamal, Nehemias Guevara, Noemy Coreas et al. Nov 03, 2025 pp. 448-448 10.1182/blood-2025-448

Abstract Background Acute myeloid leukemia (AML) is an aggressive malignancy, so early diagnosis and timely therapy initiation are critical...

A pre-NGS screening strategy to identify populations with high-risk clonal hematopoiesis

Riya Nandi, Caitlyn Vlasschaert, Md Mesbah Uddin et al. Nov 03, 2025 pp. 1386-1386 10.1182/blood-2025-1386

Abstract Background: Myeloid neoplasms (MN) often originate in the bone marrow as premalignant clonal hematopoiesis (CH), the age-related ex...

NEO-201-based CAR NK cells as a novel immunotherapeutic approach to target truncated core 1 O-glycans in AML

Joseph Clara, Mala Chakraborty, Kwong Tsang et al. Nov 03, 2025 pp. 7645-7645 10.1182/blood-2025-7645

Abstract Introduction: Despite therapeutic advances, acute myeloid leukemia (AML) continues to have poor long-term outcomes, particularly in...

TCR-T cells targeting a public neoantigen produced by the SF3B1 K700E mutation kill SF3B1-mutant AML/MDS

Noah Tubo, Duncheng Wang, Qiuming He et al. Nov 03, 2025 pp. 2363-2363 10.1182/blood-2025-2363

Abstract Myelodysplastic syndrome (MDS) is a life-threatening disease in which malignant bone marrow cells fail to differentiate, resulting...

ETNK1 mutations define a distinct subset of myeloid neoplasms with unique cytogenetic and molecular features

Steven Tessier, Najla Al Ali, Michael Trinh et al. Nov 03, 2025 pp. 3864-3864 10.1182/blood-2025-3864

Abstract Background: Mutations in ethanolamine kinase-1 (ETNK1) have been identified in a wide range of myeloid neoplasms (MN), but their cli...

Proteomic study of extracellular vesicles reveals novel biomarkers for pathogenesis of immune thrombotic thrombocytopenic purpura

Li Zhou, Ling Chen, Monish Kumar et al. Nov 03, 2025 pp. 4873-4873 10.1182/blood-2025-4873

Abstract Background: Immune thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies...

ASXL1 and NOTCH1 mutations independently predict TKI treatment failure in chronic myeloid leukemia

Tian Zeng, Xiudi Yang, Rumeng Li et al. Nov 03, 2025 pp. 5551-5551 10.1182/blood-2025-5551

Abstract Background: While tyrosine kinase inhibitors (TKIs) have improved outcomes in chronic myeloid leukemia (CML), a subset of patients...

Inhibition of CPT1A reverses AML1-ETO-induced differentiation blockage by activating BCL-2/MYC signaling and metabolic reprogramming

Shaowei Qiu, Fan Ding, Yu Liu et al. Nov 03, 2025 pp. 3224-3224 10.1182/blood-2025-3224

Abstract Objectives: Recent studies have increasingly highlighted the pivotal role of fatty acid metabolism in regulating hematopoietic stem...

Transition to IRD maintenance after DRD induction significantly deepens response in transplant-ineligible NDMM: A prospective multicenter study

Qiuqing Xiang, Minqiu Lu, Bin Chu et al. Nov 03, 2025 pp. 4059-4059 10.1182/blood-2025-4059

Abstract Background: The DRd regimen (daratumumab/lenalidomide/dexamethasone) has become a cornerstone of therapy for newly diagnosed multipl...

Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas

Christina Poh, Jasmine Zain, James Godfrey et al. Nov 03, 2025 pp. 1861-1861 10.1182/blood-2025-1861

Abstract Background T-cell lymphomas (TCL) have limited treatment options and poor prognosis, representing an unmet medi...

Trial in progress: A study of roginolisib in combination with ruxolitinib in patients with myelofibrosis who are unresponsive to JAK inhibitors (HEMA-MED)

Alessandro Vannucchi, Chiara Paoli, Paola Guglielmelli et al. Nov 03, 2025 pp. 3797-3797 10.1182/blood-2025-3797

Abstract Background and Significance. Inhibition of both the Phosphoinositide 3-kinase (PI3K) pathway and Janus kinase (JAK) signalling leads...

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma

Amrita Krishnan, Martin Kaiser, Rakesh Popat et al. Nov 03, 2025 pp. 4042-4042 10.1182/blood-2025-4042

Abstract Introduction: JNJ-5322 is a novel, next-generation trispecific antibody with capabilities to target dual myeloma antigens with a sin...

Novel indirubin-3-monoxime derivative I3MV-8b enhances anti-CD38 monoclonal antibody efficacy in multiple myeloma through dual proteasome and HDAC6 inhibition

Xiaoyu Zhang, Xiyue Sun, Yijie Wang et al. Nov 03, 2025 pp. 5708-5708 10.1182/blood-2025-5708

Abstract Background: Anti-CD38 monoclonal antibodies (mAbs) constitute a revolutionary class of targeted immunotherapeutic agents that have...

Integrated machine learning-based prognostic models for patients with Myelodysplastic Syndromes/neoplasms (MDS)

Xin Wang, Qiujin Shen, Saibing Qi et al. Nov 03, 2025 pp. 7385-7385 10.1182/blood-2025-7385

Abstract Introduction Prognostic models like the IPSS-R and IPSS-M focus on the biology of the disease but ignore patient-related factors su...

The effect of underlying hereditary hemolytic disorders on hospital resource utilization in babesiosis-associated hospitalizations: A national inpatient sample analysis 2016–2022

Heng Jiang, Deepika Dilip, Amit Krishnan et al. Nov 03, 2025 pp. 7976-7976 10.1182/blood-2025-7976

Abstract Title: The Effect of Underlying Hereditary Hemolytic Disorders on Hospital Resource Utilization in Babesiosis-Associated Hospitaliz...

Impact of baseline suvmax in untreated high-tumor-burden follicular lymphoma

Ikram Bouguern, Zora Marjanovic, Elise Corre et al. Nov 03, 2025 pp. 3604-3604 10.1182/blood-2025-3604

Abstract Background: Positron emission tomography is considered the reference imaging technique for the initial staging and therapeutic asses...

Impact of age on outcomes of CAR-T cell therapy in multiple myeloma, DLBCL, and follicular lymphoma: A real-world multi-center propensity-matched analysis

Mohammed Aloqaily, Moath Albliwi, Rahaf Yaghi et al. Nov 03, 2025 pp. 2773-2773 10.1182/blood-2025-2773

Abstract Background Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of relapsed and refractory hematologic m...

Pretargeted glycoengineered NK cell (PG-NK) therapy: A universal off-the-shelf platform redefining targeted cell therapy strategies in lymphoma

Supriya Chakraborty, Rajeswaran Mani, Lawrence Druhan et al. Nov 03, 2025 pp. 2358-2358 10.1182/blood-2025-2358

Abstract Chimeric Antigen Receptor T cell (CAR-T) therapy has transformed cancer treatment. However, its application is hindered by complex...

Is functional cure possible in follicular lymphoma? analysis and development of a predictive model for long-term progression-free (PFS15) patients

Andrea Rivero, Monica Molina, Laura Julià et al. Nov 03, 2025 pp. 5386-5386 10.1182/blood-2025-5386

Abstract Introduction: Follicular lymphoma (FL) is an indolent lymphoma characterized by a chronic course with remissions and relapses. Whil...

Impact of preexisting mental health disorders and psychiatric pharmacotherapy on hospital length of stay in immune effector cell therapy recipients

Chad Markey, William Patterson, Jaini Shah et al. Nov 03, 2025 pp. 4518-4518 10.1182/blood-2025-4518

Abstract Introduction Chimeric antigen receptor T-cell therapy (CAR-T) and bispecific T-cell engagers (BiTE) have revolutionized cancer trea...

Vorinostat for GVHD prophylaxis in children, adolescents, and young adults (AYA) shows low incidence of acute GVHD and relapse with encouraging overall survival after allogeneic hematopoietic cell transplantation (HCT): A multisite, nonrandomized clinical trial

Nicolas Parnell, Kristen Votruba, Xiao Cao et al. Nov 03, 2025 pp. 2451-2451 10.1182/blood-2025-2451

Abstract Background: Graft-versus-host disease (GVHD) remains a significant complication following allogeneic HCT. At lower doses, histone d...

ROCK2 inhibition attenuates CTL-mediated platelet destruction by suppressing IL-6/STAT3-driven glycolysis in primary immune thrombocytopenia

Juanjuan Song, Xinguang Liu, Hu Zhou Nov 03, 2025 pp. 3012-3012 10.1182/blood-2025-3012

Abstract Abstract Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by excessive platelet destruction, in which...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page